Phase II trial of trastuzumab (Herceptin), bevacizumab, and docetaxel (Taxotere) trial in stage IV metastatic breast cancer (MBC) patients
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 15 May 2017
At a glance
- Drugs Bevacizumab (Primary) ; Docetaxel (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 14 Jan 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Nov 2012, according to ClinicalTrials.gov record.
- 29 Oct 2015 Planned primary completion date changed from 1 Aug 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record.